ACCESSWIRE

4284 articles with ACCESSWIRE

• Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

  3/30/2023

  Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today reported financial results for the year ended December 31, 2022 and business highlights.

• Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

  3/30/2023

  Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022.

• Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

  3/30/2023

  Aptevo Therapeutics Inc. announced that the Company has raised $9.6 million in non-dilutive funding, extending its cash runway beyond 12 months with an additional $50,000 possible based on IXINITY sales in Q123.

• New Imaging Method for Evaluating Transport of Oxygen to Cells

  3/30/2023

  In cooperation with Perimed AB, researchers from the Department of Biomedical Engineering at Linköping University, Sweden, have developed a new method for imaging microvascular blood flow in video-rate that enables new aspects of evaluating the vital transport of oxygen to cells.

• Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity - March 30, 2023

  3/30/2023

  Biodexa Pharmaceuticals PLC announces that it has issued to various investors 6,218,265 new ordinary shares of £0.02 each in the Company, pursuant to exercise notices in respect of 1,243,653 B Warrants received yesterday.

• AlzeCure Presents New Data at Alzheimer’s Conference AD/PD on the Potential Disease-Modifying Effect of NeuroRestore ACD856

  3/30/2023

  AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website.

• Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022

  3/30/2023

  Poolbeg Pharma Plc a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, is pleased to announce its audited results for the year ended 31 December 2022.

• Moderna Finalizes Agreement with the Government of the Republic of Kenya to Establish an mRNA Manufacturing Facility

  3/30/2023

  Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, and the Government of the Republic of Kenya have finalized an agreement to establish an mRNA manufacturing facility in the Republic of Kenya.

• Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

  3/30/2023

  Halberd Corporation (OTC PINK:HALB) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU.

• First Patients Treated with TISSIUM’s Atraumatic Sutureless Nerve Coaptation System

  3/30/2023

  TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic tissue reconstruction, announced today the successful implantations of the first patients with its COAPTIUM Connect Sutureless Nerve Coaptation System as part of its peripheral nerve repair study in Australia.

• Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year of 2022

  3/29/2023

  Vaso Corporation ("Vaso") (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022.

• Envision Pharma Group Appoints Life Science Industry Expert James Streeter as New President of Technology, CTO

  3/29/2023

  Envision Pharma Group has appointed James "Jim" Streeter to the role of President of Technology, CTO and a member of the Executive Leadership Team.

• Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity - March 29, 2023

  3/29/2023

  Biodexa Pharmaceuticals PLC, a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has issued to various investors 18,636,190 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 1,738,136 A Warrants and 1,989,102 B Warrants received yesterday.

• Decoding mRNA for Early Disease Detection, Treatment & Prevention

  3/29/2023

  Ludwig Enterprises, Inc. (OTC PINK:LUDG): Personalized genetic sequencing has taken a front seat in current healthcare attempts to optimize diagnosis and treatment of devastating diseases such as cancer, heart disease and stroke.

• Spago Nanomedical Publishes the Annual Report for 2022

  3/29/2023

  Spago Nanomedical's annual report for 2022 is from available at the company's website.

• Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates

  3/29/2023

  COMPANY TO HOST AN INVESTOR CONFERENCE CALL TODAY, WEDNESDAY, MARCH 29, 2023, AT 8:00 AM EDT.

• Biodexa Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity

  3/28/2023

  Biodexa Pharmaceuticals PLC announces that it has issued to various US investors 7,473,095 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 848,068 A Warrants and 646,551 B Warrants received yesterday.

• Peak Pharmaceuticals Merges with Retrieve Medical, Inc.

  3/28/2023

  Peak Pharmaceuticals, Inc. (OTC Pink:PKPH) ("Peak" or the "Company"), announced that it has merged with Retrieve Medical, Inc., a software company that is commercializing a patented Clinical Documentation Improvement (CDI) platform, Retrieve DxTM, that enhances physicians' ability to quickly understand the complex clinical history of patients and diagnose chronic conditions by analyzing physician notes, lab results, radiology reports, EKG interpretations and more.

• Evotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year

  3/28/2023

  Evotec SE reported preliminary financial results and corporate updates for the fiscal year ended 31 December 2022.

• CureVac Announces Voting Results of Extraordinary General Meeting

  3/28/2023

  CureVac N.V., a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the voting results of the Company's extraordinary general meeting.